Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by Two Sigma Investments LP

Two Sigma Investments LP lowered its holdings in Twist Bioscience Co. (NASDAQ:TWST) by 17.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 347,532 shares of the company’s stock after selling 72,056 shares during the quarter. Two Sigma Investments LP owned 0.58% of Twist Bioscience worth $16,150,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in TWST. Van ECK Associates Corp increased its stake in shares of Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after acquiring an additional 267 shares during the period. Banque Transatlantique SA acquired a new stake in Twist Bioscience during the fourth quarter valued at $43,000. US Bancorp DE grew its position in Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after buying an additional 601 shares during the period. KBC Group NV grew its position in Twist Bioscience by 71.4% during the fourth quarter. KBC Group NV now owns 2,942 shares of the company’s stock valued at $137,000 after buying an additional 1,226 shares during the period. Finally, Teza Capital Management LLC acquired a new stake in Twist Bioscience during the fourth quarter valued at $204,000.

Analysts Set New Price Targets

Several analysts recently commented on TWST shares. JPMorgan Chase & Co. dropped their price target on shares of Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating on the stock in a research report on Tuesday, May 6th. Barclays dropped their target price on shares of Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating on the stock in a research report on Thursday, April 10th. Robert W. Baird dropped their target price on shares of Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 6th. Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Finally, Guggenheim reiterated a “buy” rating and issued a $50.00 target price on shares of Twist Bioscience in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $50.40.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 5,042 shares of the firm’s stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $37.65, for a total transaction of $189,831.30. Following the sale, the chief executive officer now directly owns 655,432 shares of the company’s stock, valued at $24,677,014.80. This trade represents a 0.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Dennis Cho sold 689 shares of the stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $37.65, for a total transaction of $25,940.85. Following the transaction, the insider now owns 110,849 shares in the company, valued at approximately $4,173,464.85. The trade was a 0.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 18,991 shares of company stock valued at $742,654 in the last ninety days. 3.01% of the stock is currently owned by company insiders.

Twist Bioscience Stock Down 1.1%

TWST stock opened at $28.16 on Friday. The company has a fifty day moving average price of $36.96 and a 200 day moving average price of $42.95. Twist Bioscience Co. has a 12 month low of $27.80 and a 12 month high of $60.90. The company has a market cap of $1.69 billion, a price-to-earnings ratio of -8.33 and a beta of 2.54. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.10). The firm had revenue of $92.79 million for the quarter, compared to analysts’ expectations of $92.00 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. Sell-side analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.